Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding ...
BioPharma Dive

Pfizer wins bidding war for Metsera with $10B offer

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a ...

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.
Fierce Biotech

Pfizer beats out Novo with $10B agreement to buy Metsera

After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has ...
BioSpace

Is Metsera Worth The Fuss?

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

(NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per ...